focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Regulatory News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,292.00
Bid: 12,288.00
Ask: 12,294.00
Change: -72.00 (-0.58%)
Spread: 6.00 (0.049%)
Open: 12,358.00
High: 12,358.00
Low: 12,288.00
Prev. Close: 12,364.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Notice of AGM

16 Mar 2017 11:00

RNS Number : 6757Z
AstraZeneca PLC
16 March 2017
 

16 March 2017 11:00 GMT

 

NOTICE OF ANNUAL GENERAL MEETING

 

AstraZeneca PLC (the Company) announced today the publication of its Notice of Annual General Meeting 2017 and Shareholders' Circular, together with a covering letter from the Chairman.

 

Copies of the documents have been submitted to the National Storage Mechanism and will shortly be available for inspection at www.morningstar.co.uk/uk/nsm. The documents are also available on the Company's website at www.astrazeneca.com/agm.

 

The Company's Annual Report and Form 20-F Information 2016 was published on 7 March 2017.

 

The above documents are being despatched to shareholders today.

 

The meeting place for the Annual General Meeting (AGM) will be the Park Plaza London Riverbank Hotel, 18 Albert Embankment, London SE1 7TJ and the AGM will commence at 2.30 pm (BST) on 27 April 2017.

 

 

A C N Kemp

Company Secretary

 

 

 

About AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three main therapy areas - Oncology, Cardiovascular & Metabolic Diseases and Respiratory. The Company also is selectively active in the areas of Autoimmunity, Neuroscience and Infection. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information, please visit www.astrazeneca.com and follow us on Twitter @AstraZeneca.

 

Media Enquiries

 

 

 

 

 

Esra Erkal-Paler

UK/Global

+44 203 749 5638

Vanessa Rhodes

 

UK/Global

 

+44 203 749 5736

 

Karen Birmingham

 

UK/Global

 

+44 203 749 5634

 

Rob Skelding

 

UK/Global

 

+44 203 749 5821

 

Jacob Lund

 

Sweden

 

+46 8 553 260 20

 

Michele Meixell

 

US

 

+1 302 885 2677

 

Investor Relations

Thomas Kudsk Larsen

 

 

 

+44 203 749 5712

 

Craig Marks

 

Finance, Fixed Income, M&A

 

+44 7881 615 764

 

Henry Wheeler

 

Oncology

 

+44 203 749 5797

 

Mitchell Chan

 

Oncology

 

+1 240 477 3771

 

Lindsey Trickett

 

Cardiovascular & Metabolic Diseases

 

+1 240 543 7970

 

Nick Stone

 

Respiratory

 

+44 203 749 5716

 

Christer Gruvris

Autoimmunity, Neuroscience & Infection

+44 203 749 5711

US toll free

+1 866 381 7277

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NOAGGUQUWUPMGUQ
Date   Source Headline
27th Apr 20227:00 amRNSEnhertu granted BTD for HER2-low breast cancer
25th Apr 20227:00 amRNSTremelimumab US Priority Review for Imfinzi combo
19th Apr 20227:00 amRNSEnhertu granted Priority Review for HER2m NSCLC
1st Apr 20223:00 pmRNSTotal Voting Rights
29th Mar 20227:00 amRNSOndexxya approved in Japan for FXai reversal
28th Mar 20227:00 amRNSEvusheld approved in the EU for COVID-19
25th Mar 20223:30 pmRNSDirector/PDMR Shareholding
24th Mar 20226:00 pmRNSEvusheld Positive EU CHMP Opinion
24th Mar 20227:00 amRNSUpdate on CALLA Phase III trial for Imfinzi
23rd Mar 202211:00 amRNSNotice of AGM
17th Mar 20227:00 amRNSSettlement of patent litigation for Ultomiris
14th Mar 20227:05 amRNSLynparza approved in US for early breast cancer
14th Mar 20227:00 amRNSUpdate on US review of Fasenra in nasal polyps
9th Mar 20223:30 pmRNSDirector/PDMR Shareholding
7th Mar 20223:30 pmRNSDirector/PDMR Shareholding
1st Mar 20223:30 pmRNSDirector/PDMR Shareholding
1st Mar 20223:00 pmRNSTotal Voting Rights
1st Mar 20227:00 amRNSAstraZeneca and Neurimmune close deal for NI006
23rd Feb 20227:00 amRNSFiling of Form 20-F with SEC
22nd Feb 202211:00 amRNSChair succession planning update and Annual Report
21st Feb 20227:00 amRNSEnhertu improves PFS and OS in HER2-low BC
16th Feb 20227:00 amRNSSaphnelo approved in EU for SLE
15th Feb 20227:00 amRNSLynparza combo delays progression risk in prostate
11th Feb 20223:30 pmRNSDirector/PDMR Shareholding
10th Feb 20227:00 amRNSAZN: Full year and Q4 2021 results
1st Feb 20223:00 pmRNSTotal Voting Rights
19th Jan 20227:05 amRNSImfinzi improves survival in biliary tract cancer
19th Jan 20227:00 amRNSImfinzi combo shows unprecedented survival in HCC
17th Jan 20227:00 amRNSEnhertu granted Priority Review for breast cancer
7th Jan 20227:00 amRNSAstraZeneca and Neurimmune sign deal for NI006
5th Jan 20227:00 amRNSTransfer of rights to Eklira, Duaklir completed
4th Jan 20223:00 pmRNSTotal Voting Rights
29th Dec 20217:00 amRNSAstraZeneca and Ionis close eplontersen deal
21st Dec 20217:00 amRNSUltomiris accepted for FDA Priority Review for gMG
20th Dec 20217:05 amRNSTezspire approved in the US for severe asthma
20th Dec 20217:00 amRNSSaphnelo recommended for EU approval for SLE
15th Dec 20213:00 pmRNSDirector/PDMR Shareholding
9th Dec 20217:00 amRNSEvusheld US FDA EUA
7th Dec 20217:00 amRNSAstraZeneca, Ionis to collaborate on eplontersen
1st Dec 20213:00 pmRNSBlock listing Interim Review
1st Dec 20213:00 pmRNSTotal Voting Rights
30th Nov 20217:00 amRNSLynparza granted FDA Priority Review for OlympiA
15th Nov 20214:00 pmRNSDirector/PDMR Shareholding
12th Nov 20217:00 amRNSAZN: Year to date and Q3 2021 results
1st Nov 20213:00 pmRNSTotal Voting Rights
1st Nov 20217:00 amRNSAstraZeneca to transfer rights to Eklira, Duaklir
25th Oct 20217:00 amRNSImfinzi improved survival in biliary tract cancer
18th Oct 20217:00 amRNSAZ recommends ADS holders reject mini-tender offer
15th Oct 20217:00 amRNSImfinzi & tremelimumab improved OS in liver cancer
11th Oct 20217:00 amRNSAZD7442 PhIII trial positive in COVID outpatients

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.